نتائج البحث

[Guidelines for managing adverse reactions to antibody-drug conjugates in breast cancer (2025 edition)].

• Authors : China Anti-Cancer Association, Breast Cancer Professional Committee; Maternal and Child Health Research Society of China, Breast Cancer Prevention and Treatment Research Professional Committee

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/adverse effects ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/therapeutic use

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2026 Mar 23; Vol. 48 (3), pp. 325-344.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

[Efficacy and safety of SOX regimen combined with Pembrolizumab in the treatment of metastatic gastric cancer].

• Authors : Zhao W; Department of Oncology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Wuxi 214111, China.; Yan J

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2026 Apr 23; Vol. 48 (4), pp. 544-552.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

[A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma].

• Authors : Ren Y; The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.; Zhao LJ

Subjects: Melanoma*/Melanoma*/Melanoma*/drug therapy ; Melanoma*/Melanoma*/Melanoma*/pathology ; Bevacizumab*/Bevacizumab*/Bevacizumab*/administration & dosage

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2026 Apr 23; Vol. 48 (4), pp. 571-585.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

Disease burden trend analysis of adverse effects of medical treatment in Chinese residents from 1990 to 2021.

• Authors : XIONG, Huan¹; YANG, Xiu-juan¹; YIN, Ruo-yun¹

• Source: Modern Preventive Medicine. 2026, Vol. 53 Issue 1, p26-31. 6p.

تفاصيل العنوان

[Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)].

• Authors : China Anti-Cancer Association, Non-Small Cell Lung Cancer Professional Committee; China Anti-Cancer Association, Cancer Drug Clinical Research Committee

Subjects: Antigens, Neoplasm*/Antigens, Neoplasm*/Antigens, Neoplasm*/immunology ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Cell Adhesion Molecules*/Cell Adhesion Molecules*/Cell Adhesion Molecules*/immunology

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2026 Mar 23; Vol. 48 (3), pp. 359-374.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

Toward pecision-based prevention: trends in the burden of adverse effects of medical treatment in China based on GBD data and identification of high-risk elderly male groups

• Authors : LI Qiongqiong; YE Dan

Subjects: adverse effects of medical treatment; aged; disease burden

• Source: 陆军军医大学学报, Vol 48, Iss 4, Pp 514-522 (2026)

تفاصيل العنوان

[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].

• Authors : Jia YF; Department of Breast Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang 110000, China.; Xia J

Subjects: Anemia*/Anemia*/Anemia*/drug therapy ; Anemia*/Anemia*/Anemia*/etiology ; Anemia*/Anemia*/Anemia*/blood

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2026 Apr 23; Vol. 48 (4), pp. 525-535.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

[Comparison of adjuvant S-1 plus gemcitabine with S-1 monotherapy for pancreatic adenocarcinoma: real-world data].

• Authors : Tang H; Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College Peking Union Medical College Hospital, Beijing 100730, China Department of Internal Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College Peking Union Medical College Hospital, Beijing 100730, China.; Li ZX

Subjects: Tegafur*/Tegafur*/Tegafur*/adverse effects ; Tegafur*/Tegafur*/Tegafur*/therapeutic use ; Tegafur*/Tegafur*/Tegafur*/administration & dosage

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2025 Dec 23; Vol. 47 (12), pp. 1284-1302.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

[Camrelizumab combined with tegafur gimeracil oteracil potassium (S-1) and nab-paclitaxel for the treatment of initially unresectable cholangiocarcinoma].

• Authors : Liao XF; Graduate Training Base of Xiangyang Central Hospital of Wuhan University of Science and Technology, Xiangyang 441021, China.; Zhao WJ

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Bile Duct Neoplasms*/Bile Duct Neoplasms*/Bile Duct Neoplasms*/drug therapy

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2025 Nov 23; Vol. 47 (11), pp. 1126-1131.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان

[Clinical expert consensus on the application of long-acting granulocyte colony-stimulating factor in gynecologic malignancies (2025 edition)].

• Authors : Gynecologic Oncology Expert Committee, Chinese Society of Clinical Oncology

Subjects: Genital Neoplasms, Female*/Genital Neoplasms, Female*/Genital Neoplasms, Female*/drug therapy ; Genital Neoplasms, Female*/Genital Neoplasms, Female*/Genital Neoplasms, Female*/therapy ; Granulocyte Colony-Stimulating Factor*/Granulocyte Colony-Stimulating Factor*/Granulocyte Colony-Stimulating Factor*/therapeutic use

• Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2025 Jul 23; Vol. 47 (7), pp. 635-644.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

تفاصيل العنوان